May 21, 2014
AZ Primary Care Head Mari Nogami AstraZeneca (AZ) will use its vast clinical trial data and clinical experience acquired globally to help its sodium-glucose co-transporter 2 (SGLT-2) inhibitor Forxiga (dapagliflozin) become one of the leading products in the Japan market...read more